Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

Income Statement

Follow revenue through to earnings.

Revenue

$8,000.00

FY 2025 · Annual

+0.0% YoY

Operating Income

-$33.21M

FY 2025 · Annual

Net Income

-$32.15M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

GNLX Earnings Waterfall · TTM

NASDAQ:GNLX · Revenue to Net Income

Key Ratios

EPS$-0.88
Gross Margin-437.5%
Net Margin-28896.9%
P/E Ratio-3.9
P/S Ratio5065.3

Analysis

$8.0K of revenue converted into -$31.8M of net income for the selected period. Gross margin is -437.5% and net margin is -28896.9%, showing how much revenue survives after costs and taxes. EPS is $-0.88, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 5, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
SC 13G/ASC 13G/A filingNov 4, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

How much revenue does GNLX generate?

Genelux Corporation (GNLX) reported $8,000.00 of revenue in fiscal 2025.

Is GNLX profitable?

Genelux Corporation (GNLX) reported -$32.15M of net income, with a net margin of -401812.5%.